2024-03-28T20:38:36Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1801852021-12-27T15:59:35Zcom_10261_35com_10261_5com_10261_31com_10261_3col_10261_288col_10261_284
Comas, Laura
Polo, Ester
Domingo, María Pilar
Hernández, Yulán
Arias, Maykel
Esteban, Patricia
Martínez Lostao, Luis
Pardo, Julián
Fuente, Jesús M. de la
Gálvez Buerba, Eva Mª
2019-04-16T08:49:27Z
2019-04-16T08:49:27Z
2019-04-02
Materials 12(7): 1092 (2019)
1996-1944
http://hdl.handle.net/10261/180185
10.3390/ma12071092
http://dx.doi.org/10.13039/501100010067
http://dx.doi.org/10.13039/501100003329
http://dx.doi.org/10.13039/501100000780
http://dx.doi.org/10.13039/501100003339
http://dx.doi.org/10.13039/501100011033
30987007
Gliotoxin (GT), a secondary metabolite produced by Aspergillus molds, has been proposed as a potential anti-tumor agent. Here we have developed a nanoparticle approach to enhance delivery of GT in tumor cells and establish a basis for its potential use as therapeutical drug. GT bound to magnetic nanoparticles (MNPs) retained a high anti-tumor activity, correlating with efficient intracellular delivery, which was increased in the presence of glucose. Our results show that the attachment of GT to MNPs by covalent bonding enhances intracellular GT delivery without affecting its biological activity. This finding represents the first step to use this potent anti-tumor agent in the treatment of cancer.
http://creativecommons.org/licenses/by-nc-sa/4.0/
openAccess
Magnetic nanoparticles
Gliotoxin
Therapeutic
Drug delivery
Cancer cells
Intracellular delivery of biologically-active fungal metabolite gliotoxin using magnetic nanoparticles
artículo